Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
-
ORGANIZATION Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
-
REGULATORY Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
-
REGULATORY DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
-
BUSINESS Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
-
ORGANIZATION Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
-
BUSINESS MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
-
REGULATORY LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
-
BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
-
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
-
REGULATORY Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
-
REGULATORY Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
-
BUSINESS Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
-
REGULATORY DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
-
ORGANIZATION Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
-
BUSINESS Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
-
REGULATORY Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
-
COMMENTARY With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
REGULATORY MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…